ARMONAIR RESPICLICK Drug Patent Profile
✉ Email this page to a colleague
When do Armonair Respiclick patents expire, and when can generic versions of Armonair Respiclick launch?
Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. There are twelve patents protecting this drug.
This drug has two hundred and seventy-nine patent family members in thirty-one countries.
The generic ingredient in ARMONAIR RESPICLICK is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-eight suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Armonair Respiclick
A generic version of ARMONAIR RESPICLICK was approved as fluticasone propionate by FOUGERA PHARMS on May 14th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ARMONAIR RESPICLICK?
- What are the global sales for ARMONAIR RESPICLICK?
- What is Average Wholesale Price for ARMONAIR RESPICLICK?
Summary for ARMONAIR RESPICLICK
| International Patents: | 279 |
| US Patents: | 12 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 86 |
| Patent Applications: | 5,456 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ARMONAIR RESPICLICK |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ARMONAIR RESPICLICK |
| DailyMed Link: | ARMONAIR RESPICLICK at DailyMed |
Pharmacology for ARMONAIR RESPICLICK
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for ARMONAIR RESPICLICK
ARMONAIR RESPICLICK is protected by twelve US patents and three FDA Regulatory Exclusivities.
Patents protecting ARMONAIR RESPICLICK
Dose counters for inhalers, inhalers and methods of assembly thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dose counter for inhaler having an anti-reverse rotation actuator
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Airflow adaptor for a breath-actuated dry powder inhaler
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dose counter for inhaler having an anti-reverse rotation actuator
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dry powder inhalation apparatus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dry powder inhalation apparatus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Airflow adaptor for a breath-actuated dry powder inhaler
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dose counters for inhalers, inhalers and methods of assembly thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dose counters for inhalers, inhalers and methods of assembly thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dry powder inhalation apparatus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Process for preparing a medicament
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Dose counter for inhaler having a bore and shaft arrangement
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting ARMONAIR RESPICLICK
NEW STRENGTH
Exclusivity Expiration: ⤷ Sign Up
PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷ Sign Up
NEW PATIENT POPULATION
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-003 | Jan 27, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-002 | Jan 27, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-003 | Jan 27, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ARMONAIR RESPICLICK
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-003 | Jan 27, 2017 | ⤷ Sign Up | ⤷ Sign Up |
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-001 | Jan 27, 2017 | ⤷ Sign Up | ⤷ Sign Up |
| Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-001 | Jan 27, 2017 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ARMONAIR RESPICLICK
See the table below for patents covering ARMONAIR RESPICLICK around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Croatia | P20150103 | ⤷ Sign Up | |
| China | 114917437 | 具有集成电子模块的吸入装置 (INHALATION DEVICE WITH INTEGRATED ELECTRONIC MODULE) | ⤷ Sign Up |
| Cyprus | 1113531 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ARMONAIR RESPICLICK
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1305329 | SPC/GB08/026 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116 |
| 2506844 | SPC/GB18/020 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117 |
| 2506844 | 1890025-8 | Sweden | ⤷ Sign Up | PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
